Market Place
Sourcing Support
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
27 Sep 2023 //
BUSINESSWIRE
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
17 Jul 2023 //
BUSINESSWIRE
Novan Enters into Agreement to Sell Substantially All of its Assets
17 Jul 2023 //
GLOBENEWSWIRE
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
05 Jun 2023 //
GLOBENEWSWIRE
Novan Focuses Strategic Direction and Announces Restructuring
31 May 2023 //
GLOBENEWSWIRE
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
08 May 2023 //
GLOBENEWSWIRE
Novan Announces Publication of Psoriasis Patient Data Demonstrating
27 Apr 2023 //
GLOBENEWSWIRE
Novan to Host Analyst and Investor Event: A Discussion of Molluscum
20 Apr 2023 //
GLOBENEWSWIRE
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
30 Mar 2023 //
GLOBENEWSWIRE
Novan to Report Full Year 2022 Financial Results on March 30, 2023
23 Mar 2023 //
GLOBENEWSWIRE
Novan Announces Closing of $6.0 Million Registered Direct Offering
16 Mar 2023 //
GLOBENEWSWIRE
Novan Announces $6.0 Million Registered Direct Offering
14 Mar 2023 //
GLOBENEWSWIRE
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
14 Mar 2023 //
GLOBENEWSWIRE
FDA Accepts Novan NDA for Berdazimer Gel
07 Mar 2023 //
GLOBENEWSWIRE
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
18 Jan 2023 //
GLOBENEWSWIRE
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel
06 Jan 2023 //
GLOBENEWSWIRE
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato
21 Dec 2022 //
GLOBENEWSWIRE
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
02 Dec 2022 //
GLOBENEWSWIRE
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology
01 Dec 2022 //
GLOBENEWSWIRE
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
07 Nov 2022 //
GLOBENEWSWIRE
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted
14 Oct 2022 //
GLOBENEWSWIRE
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA®
15 Sep 2022 //
GLOBENEWSWIRE
Novan Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Novan Satisfies $16.5 Million Outstanding Promissory Note
19 Jul 2022 //
GLOBENEWSWIRE
Novan to Publish Positive Results from Pivotal PIII Study of Berdazimer Gel
13 Jul 2022 //
PRNEWSWIRE
Novan Announces Closing of Approximately $15.0M Registered Direct Offering
13 Jun 2022 //
GLOBENEWSWIRE
Novan Announces Approximately $15.0M Registered Direct Offering
09 Jun 2022 //
GLOBENEWSWIRE
Enforcement Report - Week Of June 01, 2022
01 Jun 2022 //
FDA
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data
19 May 2022 //
GLOBENEWSWIRE
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 May 2022 //
GLOBENEWSWIRE
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
06 May 2022 //
GLOBENEWSWIRE
Novan to Participate in Virtual Investor Innovation in Dermatology Event
20 Apr 2022 //
GLOBENEWSWIRE
Novan Announces Late-Breaking Abstract Accepted for Presentation at AAD
24 Mar 2022 //
GLOBENEWSWIRE
Novan, Inc. to Present at Two Upcoming Investor Conferences
14 Mar 2022 //
GLOBENEWSWIRE
Novan Acquires EPI Health, a Specialty Dermatology Company
11 Mar 2022 //
GLOBENEWSWIRE
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019
09 Nov 2021 //
GLOBENEWSWIRE
Novan Appoints Brian as CCO; Receives Conditional FDA Acceptance of KINSOLUS
02 Nov 2021 //
GLOBENEWSWIRE
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
23 Sep 2021 //
GLOBENEWSWIRE
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
20 Sep 2021 //
GLOBENEWSWIRE
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
08 Sep 2021 //
GLOBENEWSWIRE
Novan Appoints Tomoko Maeda-Chubachi as Chief Medical Officer
24 Aug 2021 //
GLOBENEWSWIRE
Novan Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients
28 Jul 2021 //
GLOBENEWSWIRE
Novan Announces Inclusion in Russell Microcap® Index
24 Jun 2021 //
GLOBENEWSWIRE
Novan Announces Closing of $40 Million Public Offering of Common Stock
21 Jun 2021 //
GLOBENEWSWIRE
Novan Announces Pricing of $40 Million Public Offering of Common Stock
17 Jun 2021 //
GLOBENEWSWIRE
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
10 Jun 2021 //
GLOBENEWSWIRE
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206
01 Feb 2021 //
GLOBENEWSWIRE
Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement
29 Jan 2021 //
GLOBENEWSWIRE
Novan Provides Enrollment Update and Announces New Corporate Headquarters
19 Jan 2021 //
GLOBENEWSWIRE
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium
21 Dec 2020 //
GLOBENEWSWIRE
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206
15 Dec 2020 //
GLOBENEWSWIRE
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3
03 Sep 2020 //
GLOBENEWSWIRE
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study for Treatment of Molluscum
31 Aug 2020 //
GLOBENEWSWIRE
Novan Anticipates Current Cash Position Provides Sufficient SB206 Ph3 Trial
25 Jun 2020 //
GLOBENEWSWIRE
Novan Announces Receipt of Written Minutes from Type C FDA Devp of SB206
30 Apr 2020 //
GLOBENEWSWIRE
Novan Announces Closing of $5.95 Million PO, including Partial Exercise
03 Mar 2020 //
GLOBENEWSWIRE
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
20 Feb 2020 //
GLOBENEWSWIRE
Novan Provides SB206 Program and Business Update
06 Feb 2020 //
GLOBENEWSWIRE
